RRH Library Newsletter, June 2017

Libraries at Rochester Regional Health

Follow this and additional works at: https://scholar.rochesterregional.org/rrhpubs

Part of the Health Sciences and Medical Librarianship Commons

Recommended Citation
Retrieved from https://scholar.rochesterregional.org/rrhpubs/691

This Newsletter is brought to you for free and open access by RocScholar. It has been accepted for inclusion in Rochester Regional Health authored publications and proceedings by an authorized administrator of RocScholar. For more information, please contact Lisa.Buda@rochesterregional.org.
For decades, warfarin (Coumadin®) has been the primary oral anticoagulant used for the treatment and prevention of abnormal blood clots and stroke prophylaxis. However, in the last few years, new oral anticoagulants have been approved for use in the United States. Known collectively as novel or direct or target-specific oral anticoagulants, they include dabigatran (Pradaxa®), apixaban (Eliquis®), rivaroxaban (Xarelto®), and edoxaban (Savaysa®).

To suggest a topic, please email wellness@rochesterregional.org. To read the full article, click the linked title or contact the Werner Medical Library.


- **Ferreira JL & Wipf JE. (2016).** *Pharmacologic therapies in anticoagulation.* Medical Clinics of North America, 100(4), 695-718.


- **Hanley CM & Kowey PR. (2015).** *Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?* Journal of Thoracic Disease, 7(2), 165-171.

- **Hicks T, et al. (2016).** *NOACs versus warfarin for stroke prevention in patients with AF: A systematic review and meta-analysis.* Open Heart, 3(1), e000279.


